About Triveni Bio
Triveni Bio is a Healthcare company based in Waltham (United States) founded in 2023. Functional antibodies are developed for immunological and inflammatory disorders. Triveni Bio has raised $272 million across 3 funding rounds from investors including Fidelity Investments, Goldman Sachs and ARE. Its chief executive, as recorded, is Vishal Patel. Triveni Bio offers products and services including Proprietary Platform and Functional Antibodies. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Triveni Bio was founded in 2023 and is based in Waltham, United States. Functional antibodies are developed by the company for treating immunological and inflammatory disorders. A mendelian genetics-informed precision medicine approach is pioneered, including TRIV-509, which targets kallikreins 5 and 7 for indications such as atopic dermatitis and asthma. Operations focus on biotechnology in the therapeutics sector.
- Headquarters Waltham, United States
- SectorsHealthcare
- Email••••••••
- Website triveni.bio
- Social LinkedIn
- Total Equity Funding$272M (USD)
in 3 rounds
- Latest Funding Round$65M (USD), Series C
Jun 2026
- InvestorsFidelity Investments
& 11 more
Products & Services of Triveni Bio
Triveni Bio offers a comprehensive portfolio of products and services, including Proprietary Platform and Functional Antibodies.
Platform for identifying and derisking therapeutic targets in immunological disorders.
Antibodies designed for treating inflammatory and immunological conditions.
Funding Insights of Triveni Bio
Triveni Bio has successfully raised a total of $272M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $65 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $272M
- Total Rounds 3
- Last Round Series C — $65M
- First Round $92M
(Oct 2023)
- Investors Count 12
All 3 funding rounds of Triveni Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $65M | Series C | – | Ascenta Capital, Janus Henderson Investors | |
| Oct 2024 | $115M | Series B | – | Goldman Sachs | |
| Oct 2023 | $92M | Series A | – | Atlas Venture, Cormorant Asset Management |
12 investors in total: 12 institutional.
Investors in Triveni Bio
Triveni Bio has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Goldman Sachs and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Investment banking services are delivered across multiple financial sectors. | 1869 | goldmansachs.com | New York, United States | |
US focused venture capital firm | polarispartners.com | Boston, United States | ||
| ascentacap.com | ||||
| janushenderson.com | ||||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States |
Investor details for Triveni Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Triveni Bio
13 people are tracked at Triveni Bio (10 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Vishal Patel | CEO | Leadership |
Eva Asp | Vp, Biology | Leadership |
Susan Wu | Vp, Development Operations And Clinical Program Management | Leadership |
Jennifer Dovey | Chief Scientific Officer | Leadership |
Brantley Herrin | Vp, Head Of Biologics Discovery | Leadership |
Kejie Li | Vp, Head Of Data Science | Leadership |
Nicholas Scarchilli | Chief Operating Officer | Leadership |
Bhaskar Srivastava | Chief Medical Officer | Leadership |
Christopher M. | Executive Director, Legal | Leadership |
Jill Sincaglia Murray | Vp, Head Of Human Resources | Leadership |
Thomas Leighton | Manager, Lab Operations | Team |
Ye Tang | Senior Scientist I | Team |
Daria Chabas | Clinical Trial Manager | Team |
Complete people profiles for Triveni Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Triveni Bio
3 dated milestones of Triveni Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Triveni Bio is founded.
- Funding First funding round of $92.0M.
- Funding Latest funding round, Series C, of $65.0M.
Competitors of Triveni Bio
Triveni Bio has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Triveni Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Triveni Bio
The website of Triveni Bio (triveni.bio) receives about 5.4K visits a month.
- Monthly visits5.4K
▲ 73.4% vs previous month
Websites whose visitors overlap most with Triveni Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
reintx.com | reintx.com | 100% | #3,977,411 | – | |
| cuebiopharma.com | 98% | 4.9K | #7,063,180 | View details | |
| fluentbio.com | 98% | 4.7K | #3,913,179 | View details | |
| sherlock.bio | 96% | 2.8K | #4,929,420 | View details | |
| ornatx.com | 94% | 4.4K | #3,250,511 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Triveni Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Triveni Bio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Triveni Bio
Complete news archive for Triveni Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Triveni Bio
Triveni Bio was founded in 2023.
Triveni Bio is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Vishal Patel is the CEO of Triveni Bio, as recorded in our data.
Triveni Bio is a funded company, having raised a total of $272M across 3 funding rounds to date. The company's 1st funding round was a Series A of $92M, raised on Oct 2023.
Triveni Bio was founded in 2023 and is based in Waltham, United States. Functional antibodies are developed by the company for treating immunological and inflammatory disorders. A mendelian genetics-informed precision medicine approach is pioneered, including TRIV-509, which targets kallikreins 5 and 7 for indications such as atopic dermatitis and asthma. Operations focus on biotechnology in the therapeutics sector.
Triveni Bio's top competitors include ADMA Biologics, Kymeratx and Biogen.
Triveni Bio offers Proprietary Platform and Functional Antibodies.
Triveni Bio has 12 investors. Key investors include Fidelity Investments, Goldman Sachs, ARE, Orbimed, and Atlas Venture.